Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07389941
PHASE4

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

Sponsor: University of Luebeck

View on ClinicalTrials.gov

Summary

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

Official title: Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2026-10

Completion Date

2029-04

Last Updated

2026-02-11

Healthy Volunteers

No

Interventions

DRUG

Semaglutide (SEMA)

Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)